Targeting A3 and A2A adenosine receptors in the fight against cancer

References

• Borea PA, Gessi S, Merighi S, et al. Pharmacology of adenosine receptors: the state of the art. Physiol Rev. 2018;98:1591–1625.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Csóka B, Fornai M, et al. Adenosine and inflammation: what’s new on the horizon? Drug Discov Today. 2014;19:1051–1068.
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Gaudreau PO, et al. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy. 2016;8:145–163.
   PubMed Web of Science ®Google Scholar
• Borea PA, Gessi S, Merighi S, et al. Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol Sci. 2016;37:419–434.
   PubMed Web of Science ®Google Scholar
• Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol. 2016;7:109.
   PubMed Web of Science ®Google Scholar
• Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57:2602–2605.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Vagman L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res. 1998;58:3181–3187.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Farbstein T, Barer F, et al. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clin Exp Metastasis. 1999;17:531–535.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Barer F, Volfsson L, et al. Resistance of muscle to tumor metastases: a role for A3 adenosine receptor agonists. Neoplasia. 2001;3:125–131.
   PubMed Web of Science ®Google Scholar
• Ohana G, Bar-Yehuda S, Barer F, et al. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol. 2001;186:19–23.
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916–920.
   PubMed Web of Science ®Google Scholar
• Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci. 2006;103:13132–13137.
   PubMed Web of Science ®Google Scholar
• Lukashev D, Ohta A, Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev. 2007;26:273–279.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Ohana G, et al. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer. 2000;36:1452–1458.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Liang BT, et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17:359–366.
   PubMed Web of Science ®Google Scholar
• Merighi S, Mirandola P, Varani K, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003;100:31–48.
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Varani K, et al. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. 2008;117:123–140.
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Sacchetto V, et al. Adenosine receptors and cancer. Biochim Biophys Acta - Biomembr. 2011;1808:1400–1412.
   Web of Science ®Google Scholar
• Gessi S, Varani K, Merighi S, et al. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br J Pharmacol. 2001;134:116–126.
   PubMed Web of Science ®Google Scholar
• Gessi S, Varani K, Merighi S, et al. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol. 2002;61:415–424.
   PubMed Web of Science ®Google Scholar
• Gessi S, Sacchetto V, Fogli E, et al. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol. 2010;79:1483–1495.
   PubMed Web of Science ®Google Scholar
• Merighi S, Varani K, Gessi S, et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol. 2001;134:1215–1226.
   PubMed Web of Science ®Google Scholar
• Merighi S, Benini A, Mirandola P, et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol. 2006;72:19–31.
   PubMed Web of Science ®Google Scholar
• Ohana G, Bar-Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer. 2003;89:1552–1558.
   PubMed Web of Science ®Google Scholar
• Jajoo S, Mukherjea D, Watabe K, et al. Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia. 2009;11:1132–1145.
   PubMed Web of Science ®Google Scholar
• Varani K, Maniero S, Vincenzi F, et al. A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. Am J Respir Crit Care Med. 2011;183:522–530.
   PubMed Web of Science ®Google Scholar
• Madi L, Ochaion A, Rath-Wolfson L, et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004;10:4472–4479.
   PubMed Web of Science ®Google Scholar
• Gessi S, Cattabriga E, Avitabile A, et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res. 2004;10:5895–5901.
   PubMed Web of Science ®Google Scholar
• Morello S, Petrella A, Festa M, et al. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther. 2008;7:278–284.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Stemmer SM, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol. 2008;33:287–295.
   PubMed Web of Science ®Google Scholar
• Merighi S, Benini A, Mirandola P, et al. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem. 2005;280:19516–19526.
   PubMed Web of Science ®Google Scholar
• Gessi S, Merighi S, Varani K, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol. 2007;211:826–836.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Barer F, et al. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 2001;269:230–236.
   PubMed Web of Science ®Google Scholar
• Morello S, Sorrentino R, Porta A, et al. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. J Cell Physiol. 2009;221:378–386.
   PubMed Web of Science ®Google Scholar
• Aghaei M, Panjehpour M, Karami-Tehrani F, et al. Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol. 2011;137:1511–1523.
   PubMed Web of Science ®Google Scholar
• Vincenzi F, Targa M, Corciulo C, et al. The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. PLoS One. 2012;7:e39317.
   PubMed Web of Science ®Google Scholar
• Fishman P, Madi L, Bar-Yehuda S, et al. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene. 2002;21:4060–4064.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Ohana G, et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene. 2004;23:2465–2471.
   PubMed Web of Science ®Google Scholar
• Merimsky O, Bar-Yehuda S, Madi L, et al. Modulation of the A 3 adenosine receptor by low agonist concentration induces antitumor and myelostimulatory effects. Drug Dev. 2003;58:386–389.
   Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Farbstein T, et al. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol. 2000;183:393–398.
   PubMed Web of Science ®Google Scholar
• Hofer M, Pospíšil M, Vacek A, et al. Effects of adenosine A3 receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice. Eur J Pharmacol. 2006;538:163–167.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Madi L, Barak D, et al. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kB activation: a new class of myeloprotective agents. Exp Hematol. 2002;30:1390–1398.
   PubMed Web of Science ®Google Scholar
• Harish A, Hohana G, Fishman P, et al. A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol. 2003;23:1245–1249.
   PubMed Web of Science ®Google Scholar
• Montinaro A, Forte G, Sorrentino R, et al. Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice. PLoS One. 2012;7:e45401.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Madi L, et al. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs. 2002;13:437–443.
   PubMed Web of Science ®Google Scholar
• Madi L, Bar-Yehuda S, Barer F, et al. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem. 2003;278:42121–42130.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Ardon E, et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 2003;23:2077–2083.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Madi L, Silberman D, et al. CF101, an agonist to the A 3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia. 2005;7:85–90.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Synowitz M, et al. Adenosine receptors and cancer. Handb Exp Pharmacol. 2009;193:399–441. Ed C N Wilson, S J Mustafa
   PubMedGoogle Scholar
• Cohen S, Stemmer SM, Zozulya G, et al. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 2011;226:2438–2447.
   PubMed Web of Science ®Google Scholar
• Varani K, Vincenzi F, Targa M, et al. The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur J Cancer. 2013;49:482–491.
   PubMed Web of Science ®Google Scholar
• Van Troostenburg AR, Clark EV, Carey WDH, et al. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther. 2004;42:534–542.
   PubMed Web of Science ®Google Scholar
• Stemmer SM, Benjaminov O, Medalia G, et al. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist. 2013;18:25–26.
   PubMed Web of Science ®Google Scholar
• Lukashev D, Sitkovsky M, Ohta A. From “Hellstrom Paradox“–to anti-adenosinergic cancer immunotherapy. Purinergic Signal. 2007;3:129–134.
   PubMed Web of Science ®Google Scholar
• Borea PA, Gessi S, Merighi S, et al. Pathological overproduction: the bad side of adenosine. Br J Pharmacol. 2017;174:1945–1960.
   PubMed Web of Science ®Google Scholar
• Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013;110:11091–11096.
   PubMed Web of Science ®Google Scholar
• Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin Ther Targets. 2014;18:863–881.
   PubMed Web of Science ®Google Scholar
• Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70:2245–2255.
   PubMed Web of Science ®Google Scholar
• Huang S, Apasov S, Koshiba M, et al. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600–1610.
   PubMed Web of Science ®Google Scholar
• Khoa ND, Montesinos MC, Reiss AB, et al. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol. 2001;167:4026–4032.
   PubMed Web of Science ®Google Scholar
• Schnurr M, Toy T, Shin A, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2003;103:1391–1397.
   PubMed Web of Science ®Google Scholar
• Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol. 2005;174:1073–1080.
   PubMed Web of Science ®Google Scholar
• Lappas CM, Sullivan GW, Linden J. Adenosine A 2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs. 2005;14:797–806.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Wiznerowicz EB, Lappas CM, et al. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol. 2006;177:2765–2769.
   PubMed Web of Science ®Google Scholar
• Bruzzese L, Fromonot J, By Y, et al. NF-κB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A2A receptors. Cell Signal. 2014;26:1060–1067.
   PubMed Web of Science ®Google Scholar
• Serra S, Vaisitti T, Audrito V, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016;1:47–61.
   PubMed Web of Science ®Google Scholar
• Guerrero A. A2A adenosine receptor agonists and their potential therapeutic applications. An update. Curr Med Chem. 2018;25:3597–3612.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Fornai M, Blandizzi C, et al. Adenosine signaling and the immune system: when a lot could be too much. Immunol Lett. 2018;205:9–15.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842–857.
   PubMed Web of Science ®Google Scholar
• Muller-Haegele S, Muller L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol. 2014;10:897–914.
   PubMed Web of Science ®Google Scholar
• Koshiba M, Kojima H, Huang S, et al. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem. 1997;272:25881–25889.
   PubMed Web of Science ®Google Scholar
• Pardoll D. T cells take aim at cancer. Proc Natl Acad Sci. 2002;99:15840–15842.
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol. 2003;65:493–501.
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia -inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004;22:657–682.
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Kjaergaard J, Lukashev D, et al. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res. 2008;14:5947–5952.
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol. 2009;30:102–108.
   PubMed Web of Science ®Google Scholar
• Romio M, Reinbeck B, Bongardt S, et al. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine treg and teff cells. Am J Physiol Cell Physiol. 2011;301:530–539.
   PubMed Web of Science ®Google Scholar
• Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332–1341.
   PubMed Web of Science ®Google Scholar
• Bao R, Shui X, Hou J, et al. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. Int J Mol Med. 2016;38:969–975.
   PubMed Web of Science ®Google Scholar
• Masjedi A, Hassannia H, Atyabi F, et al. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. Int J Biol Macromol. 2019;133:436–445.
   PubMed Web of Science ®Google Scholar
• Mediavilla-Varela M, Luddy K, Noyes D, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013;14:860–868.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73 + tumors. Proc Natl Acad Sci. 2013;110:14711–14716.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Milenkovski N, Henderson MA, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3:506–517.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Henderson MA, Giuffrida L, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127:929–941.
   PubMed Web of Science ®Google Scholar
• Mediavilla-Varela M, Castro J, Chiappori A, et al. A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment. Neoplasia. 2017;19:530–536.
   PubMed Web of Science ®Google Scholar
• Ma SR, Deng WW, Liu JF, et al. Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer. 2017;16:99.
   PubMed Web of Science ®Google Scholar
• Yuan G, Jankins TC, Patrick CG, et al. Fluorinated adenosine A 2A receptor antagonists inspired by preladenant as potential cancer immunotherapeutics. Int J Med Chem. 2017;2017:1–8.
   Web of Science ®Google Scholar
• Kjaergaard J, Hatfield S, Jones G, et al. A2A adenosine receptor gene deletion or synthetic A2A antagonist liberate tumor-reactive CD8+ T cells from tumor-induced immunosuppression. J Immunol. 2018;201:782–791.
   PubMed Web of Science ®Google Scholar
• Leone RD, Sun IM, Oh MH, et al. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother. 2018;67:1271–1284.
   PubMed Web of Science ®Google Scholar
• Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer. 2018;9:1773–1781.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–723.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625:41–54.
   PubMed Web of Science ®Google Scholar
• Soleimani A, Bahreyni A, Roshan MK, et al. Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives. J Cell Physiol. 2019;234:2329–2336.
   PubMed Web of Science ®Google Scholar
• Suvarna B. Adenosine receptors as targets for therapeutic intervention. Kathmandu Univ Med J (KUMJ). 2013;11:96–101.
   PubMedGoogle Scholar
• Ramirez-Zamora A, Molho E. Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions. Expert Rev Neurother. 2014;14:93–103.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Nagai M, Nishikawa N. Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol. 2014;119:191–194.
   PubMed Web of Science ®Google Scholar
• Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139:325–337.
   PubMed Web of Science ®Google Scholar
• Congreve M, Brown GA, Borodovsky A, et al. Targeting adenosine A2A receptor antagonism for treatment of cancer. Expert Opin Drug Discov. 2018;13:997–1003.
   PubMed Web of Science ®Google Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1a-dependent and extracellular adenosine-mediated tumor protection. J Mol Med. 2014;92:1283–1292.
   PubMed Web of Science ®Google Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015;7:277.
   Web of Science ®Google Scholar
• Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Des Devel Ther. 2019;13:491–497.
   PubMed Web of Science ®Google Scholar
• Allard D, Turcotte M, Stagg J. Targeting A2 adenosine receptors in cancer. Immunol Cell Biol. 2017;95:333–339.
   PubMed Web of Science ®Google Scholar
• Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M, et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J Cell Physiol. 2018;233:2032–2057.
   PubMed Web of Science ®Google Scholar